Utama › Mieloma Pelbagai › Iowa › Cedar Rapids
Kajian klinikal Mieloma Pelbagai di Cedar Rapids, IA
15 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Cedar Rapids (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi jauh
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Mengambil pesertaFasa 1
- Research Site, Iowa City · 25 mi jauh
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- University of Iowa Hospital and Clinics, Iowa City · 25 mi jauh
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- University of Iowa, Iowa City · 25 mi jauh
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- University of Iowa, Iowa City · 25 mi jauh
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Mengambil pesertaFasa 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Mengambil pesertaFasa 1/2
- Research Site, Iowa City · 25 mi jauh
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Mengambil pesertaFasa 3
- Research Site, Iowa City · 25 mi jauh
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- University of Iowa, Iowa City · 25 mi jauh
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Mengambil pesertaFasa 3
- Physicians' Clinic of Iowa PC, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauh
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Mengambil pesertaFasa 2
- University of Iowa, Iowa City · 25 mi jauh
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Mengambil pesertaFasa 1
- University of Iowa Health Care, Iowa City · 25 mi jauh
Sleep Apnea in Patients With MGUS and MM
Mengambil pesertaKajian pemerhatian
- University of Iowa, Iowa City · 25 mi jauh
Activity Levels in Bone Marrow Transplant Patients
Mengambil pesertaKajian pemerhatian
- University of Iowa, Iowa City · 25 mi jauh
Limited-duration Teclistamab
Mengambil pesertaFasa 2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi jauh
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
Kajian lain di Cedar Rapids
- Kanser Paru-paru Bukan Sel Kecil20 kajian
- Kanser Payudara17 kajian
- Leukemia Mieloid Akut16 kajian
- Kanser (semua jenis)15 kajian
- Kanser Paru-paru14 kajian
- Kanser Kolorektal13 kajian
- Kanser Prostat12 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher12 kajian
- Melanoma10 kajian
- Strok10 kajian
- Kanser Metastatik9 kajian
- Kanser Endometrium9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.